|Budget Amount *help
¥23,790,000 (Direct Cost: ¥18,300,000、Indirect Cost: ¥5,490,000)
Fiscal Year 2013: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
Fiscal Year 2012: ¥11,050,000 (Direct Cost: ¥8,500,000、Indirect Cost: ¥2,550,000)
Fiscal Year 2011: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2010: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
To develop novel carbohydrate-targeting biomarkers for early detection of lung cancer, glycoproteomic profiling of 144 serum samples was conducted. We further established a mass spectrometric quantification method for glycan structure alterations, named Energy resolved oxonium ion monitoring (Erexim) technology, in order for large-scaled validation study of 16 identified lung cancer biomarker candidates. The Erexim-based validation experiment using 87 independent serum samples revealed that frequency of alpha-1, 6 fucosylation on CD163-Asn105, Asn140, and Asn1027 was significantly up-regulated in even stage-I or II lung adenocarcinoma patients compared to normal control group. The Erexim technology was patented in US (US 8653448, 18.Feb.2014) and already utilized in various areas, such as chemistry, manufacturing and control (CMC) of biologics.